Department of Management, Clinical Research Center, Kurashiki Central Hospital, Kurashiki, Japan.
Department of Otolaryngology/Head and Neck Surgery, Kurashiki Central Hospital, Kurashiki, Japan.
BMJ Open. 2022 Jul 13;12(7):e055459. doi: 10.1136/bmjopen-2021-055459.
Validation studies in oncology are limited in Japan. This study was conducted to evaluate the accuracy of diagnosis and adverse event (AE) definitions for specific cancers in a Japanese health administrative real-world database (RWD).
Retrospective observational validation study to assess the diagnostic accuracy of electronic medical records (EMRs) and claim coding regarding oncology diagnosis and AEs based on medical record review in the RWD. The sensitivity and positive predictive value (PPV) with 95% CIs were calculated.
The validation cohort included patients with lung (n=2257), breast (n=1121), colorectal (n=1773), ovarian (n=216) and bladder (n=575) cancer who visited the hospital between January 2014 and December 2018, and those with prostate cancer (n=3491) visiting between January 2009 and December 2018, who were identified using EMRs.
Key outcomes included primary diagnosis, deaths and AEs.
For primary diagnosis, sensitivity and PPV for the respective cancers were as follows: lung, 100.0% (96.6 to 100.0) and 81.0% (74.9 to 86.2); breast, 100.0% (96.3 to 100.0) and 74.0% (67.3 to 79.9); colorectal, 100.0% (96.6 to 100.0) and 80.5% (74.3 to 85.8); ovarian, 89.8% (77.8 to 96.6) and 75.9% (62.8 to 86.1); bladder, 78.6% (63.2 to 89.7) and 67.3% (52.5 to 0.1); prostate, 100.0% (93.2 to 100.0) and 79.0% (69.7 to 86.5). Sensitivity and PPV for death were as follows: lung, 97.0% (84.2 to 99.9) and 100.0% (84.2 to 100.0); breast, 100.0% (1.3 to 100.0) and 100.0% (1.3 to 100.0); colorectal, 100.0% (28.4 to 100.0) and 100.0% (28.4 to 100.0); ovarian, 100.0% (35.9 to 100.0) and 100.0% (35.9 to 100.0); bladder, 100.0% (9.4-100.0) and 100.0% (9.4 to 100.0); prostate, 75.0% (19.4 to 99.4) and 100.0% (19.4 to 100.0). Overall, PPV tended to be low, with the definition based on International Classification of Diseases, 10th revision alone for AEs.
Diagnostic accuracy was not so high, and therefore needs to be further investigated.
University Hospital Medical Information Network (UMIN) Clinical Trials Registry (UMIN000039345).
在日本,肿瘤学的验证研究有限。本研究旨在评估日本健康管理真实世界数据库(RWD)中特定癌症的诊断准确性和不良事件(AE)定义。
回顾性观察性验证研究,通过对 RWD 中的医疗记录审查,评估电子病历(EMR)和索赔编码在肿瘤学诊断和 AE 方面的准确性。计算了灵敏度和阳性预测值(PPV)及其 95%置信区间。
验证队列包括 2014 年 1 月至 2018 年 12 月期间在医院就诊的肺癌(n=2257)、乳腺癌(n=1121)、结直肠癌(n=1773)、卵巢癌(n=216)和膀胱癌(n=575)患者,以及 2009 年 1 月至 2018 年 12 月期间就诊的前列腺癌(n=3491)患者,这些患者均通过 EMR 识别。
主要结局包括主要诊断、死亡和 AE。
对于主要诊断,各癌症的灵敏度和 PPV 如下:肺癌,100.0%(96.6 至 100.0)和 81.0%(74.9 至 86.2);乳腺癌,100.0%(96.3 至 100.0)和 74.0%(67.3 至 79.9);结直肠癌,100.0%(96.6 至 100.0)和 80.5%(74.3 至 85.8);卵巢癌,89.8%(77.8 至 96.6)和 75.9%(62.8 至 86.1);膀胱癌,78.6%(63.2 至 89.7)和 67.3%(52.5 至 86.5);前列腺癌,100.0%(93.2 至 100.0)和 79.0%(69.7 至 86.5)。死亡的灵敏度和 PPV 如下:肺癌,97.0%(84.2 至 99.9)和 100.0%(84.2 至 100.0);乳腺癌,100.0%(1.3 至 100.0)和 100.0%(1.3 至 100.0);结直肠癌,100.0%(28.4 至 100.0)和 100.0%(28.4 至 100.0);卵巢癌,100.0%(35.9 至 100.0)和 100.0%(35.9 至 100.0);膀胱癌,100.0%(9.4 至 100.0)和 100.0%(9.4 至 100.0);前列腺癌,75.0%(19.4 至 99.4)和 100.0%(19.4 至 100.0)。总体而言,PPV 倾向于较低,单独使用国际疾病分类第 10 版定义 AE 时尤其如此。
诊断准确性不高,因此需要进一步研究。
日本大学医院医学信息网络(UMIN)临床试验注册(UMIN000039345)。